Cellectar Biosciences

Yahoo Finance • yesterday

Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)

FLORHAM PARK, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today annou... Full story

Yahoo Finance • last month

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Ocugen (OCGN [https://seekingalpha.com/symbol/OCGN]) * Abercrombie & Fitch Co. (ANF [https://seekingalpha.com/symbol/ANF]) * XAI Octagon Floating Rate & Alternative Inc... Full story

Yahoo Finance • 2 months ago

Cellectar Biosciences Expands Global Intellectual Property Estate

Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing Approval with the European Medicines Ag... Full story

Yahoo Finance • 4 months ago

Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies

FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of c... Full story

Yahoo Finance • 5 months ago

Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom’s Macroglobulinemia in 2026 Following Advice and Guidance from Scientific Advice Working Party (SAWP) Initia... Full story

Yahoo Finance • 5 months ago

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025

FLORHAM PARK, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announ... Full story

Yahoo Finance • 6 months ago

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announ... Full story

Yahoo Finance • 6 months ago

Cellectar Biosciences Stock Rises Over EMA's Advise On CMA Filing For Iopofosine I 131

(RTTNews) - Cellectar Biosciences, Inc. (CLRB), Monday announced that the Scientific Advice Working Party or SAWP of the European Medicines Agency has advised filing for a Conditional Marketing Authorization or CMA for iopofosine I 131 as... Full story

Yahoo Finance • 7 months ago

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

FLORHAM PARK, N.J. and GARCHING, Germany and MUNICH, Germany, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB, “Cellectar”), a late-stage clinical biopharmaceutical company focused on the discovery and develo... Full story

Yahoo Finance • 7 months ago

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Highlighting Continued Progress with EMA Regarding a Potential Conditional Marketing Authorization Submission for Iopofosine I 131 to Treat Waldenstrom Macroglobulinemia (WM) in the EU; Decision on Track for Late 3Q25/Early 4Q25 Intention... Full story

Yahoo Finance • 7 months ago

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today annou... Full story

Yahoo Finance • 7 months ago

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today annou... Full story

Yahoo Finance • 8 months ago

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

FLORHAM PARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announ... Full story

Yahoo Finance • 8 months ago

Cellectar Biosciences GAAP EPS of -$3.39 beats by $0.31

* Cellectar Biosciences press release [https://seekingalpha.com/pr/20200781-cellectar-biosciences-reports-second-quarter-2025-financial-results-and-provides-a-corporate] (NASDAQ:CLRB [https://seekingalpha.com/symbol/CLRB]): Q2 GAAP EPS o... Full story

Yahoo Finance • 8 months ago

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway C... Full story

Yahoo Finance • 8 months ago

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of c... Full story

Yahoo Finance • 9 months ago

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

FLORHAM PARK, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of canc... Full story

Yahoo Finance • 9 months ago

Cellectar Biosciences prices $6 million public offering

FLORHAM PARK, N.J. - Cellectar Biosciences, Inc. (NASDAQ:CLRB), currently valued at $9.1 million in market capitalization, has priced an underwritten public offering expected to generate approximately $6 million in gross proceeds before de... Full story

Yahoo Finance • 9 months ago

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of canc... Full story

Yahoo Finance • 10 months ago

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative Breast Cancer FLORHAM PARK, N.J. and WEST... Full story